       Document 0717
 DOCN  M95A0717
 TI    Zidovudine is beneficial in human immunodeficiency virus associated
       nephropathy.
 DT    9510
 AU    Ifudu O; Rao TK; Tan CC; Fleischman H; Chirgwin K; Friedman EA; State
       University of New York Health Science Center, Department of; Medicine,
       Brooklyn 11203, USA.
 SO    Am J Nephrol. 1995;15(3):217-21. Unique Identifier : AIDSLINE
       MED/95343939
 AB    Human immunodeficiency virus associated nephropathy (Hivan) is a
       distinct renal disease described in patients infected with the human
       immunodeficiency virus (HIV). Hivan is characterized by a nephrotic
       syndrome, enlarged kidneys, a histologic finding of focal and segmental
       glomerulosclerosis, and a very rapid progression to end-stage renal
       disease (ESRD). No therapeutic intervention has been shown, in a
       prospective evaluation, to either alter the course of established Hivan
       or to influence the emergence of Hivan in HIV-infected patients. We
       conducted a prospective study on 23 consecutively selected patients seen
       between 1989 and 1992 who were infected with the HIV, 14 (61%) of whom
       had significant proteinuria (> or = 2+). Percutaneous kidney biopsy was
       performed in 5 (36%) of the 14 subjects who had significant proteinuria,
       and histologic examination of the kidney tissue revealed focal and
       segmental glomerulosclerosis in all 5 cases. Of the 14 subjects with
       proteinuria, 8 (57%) also had azotemia (serum creatinine level > or =
       1.3 mg/dl). Nine (39%) of 23 subjects admitted intravenous drug use,
       while 9 (39%) of 23 subjects have had an opportunistic infection before
       enrollment in the study. The known duration of HIV infection before
       initiation of zidovudine therapy was 10.3 +/- (SD) 8 months. The mean
       CD4 count before zidovudine therapy was 195.9 +/- 117 (range 21-654)
       cells/mm3. The mean dose of zidovudine administered was 543 +/- 117
       (range 400-800) mg daily for a period of 20.4 +/- 11 (range 6-38)
       months.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Adult  AIDS-Associated Nephropathy/*DRUG THERAPY/EPIDEMIOLOGY/IMMUNOLOGY
       Case-Control Studies  Comparative Study  CD4 Lymphocyte Count  Disease
       Progression  Female  Human  Kidney Failure,
       Chronic/EPIDEMIOLOGY/PREVENTION & CONTROL  Male  Prospective Studies
       Zidovudine/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

